Integra LifeSciences (NASDAQ:IART) recently announced preliminary revenue results for fourth-quarter and fiscal 2019. The company is expected to release detailed financial results for the period on Feb 20.
Integra projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance of $395-$400 million.This represents an organic revenue growth of marginally less than 5% and reported growth of around 3%. The Zacks Consensus Estimate for the same is pinned at $397.9 million.
For 2019, the company projects revenue to be at or near the low end of the previously-pegged guidance range of $1.51-1.52 billion. This mirrors organic growth of slightly less than 5% and reported growth of approximately 3%. The Zacks Consensus Estimate for the same was $1.52 billion.
2020 Guidance
For 2020, the company projects revenues in the range of $1.55 -$1.57 billion, indicating organic revenue growth of nearly 5% and reported growth of 3%. The Zacks Consensus Estimate for the same is pegged at $1.59 billion.
Integra projects 2020 earnings per share (EPS) growth in double digits compared to the 2019 tally. The Zacks Consensus Estimate for 2020 adjusted EPS is pegged at $2.99.
The stock price dropped 0.3% to $58.32 at the close of the trading session on Jan 15.
Share Repurchase Update
With approval from the board of directors, Integra plans to implement a share repurchase program, with an authorization of up to $225 million.
Share Price Movement
Integra has underperformed its industry over the past three months. The stock has lost 5.9% against the 11.6% rise of the industry.
Zacks Rank & Key Picks
Currently, Integra carries a Zacks Rank #4 (Sell). A few better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , Hill-Rom Holdings, Inc (NYSE:HRC) and Omnicell (NASDAQ:OMCL) .
Haemonetics has a Zacks Rank #1 (Strong Buy) and a projected long-term earnings growth rate of 13.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hill-Rom’s long-term earnings growth rate is estimated at 11.7%. The company currently carries a Zacks Rank #2 (Buy).
Omnicell has a long-term earnings growth rate of 12.5%. The company also currently carries Zacks Rank #2.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Omnicell, Inc. (OMCL): Free Stock Analysis Report
Hill-Rom Holdings, Inc. (HRC): Free Stock Analysis Report
Haemonetics Corporation (HAE): Free Stock Analysis Report
Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report
Original post
Zacks Investment Research